National Survey Investigating Hallucinogenic Trends

The leading, most comprehensive survey of adults actively using psychedelic substances in the United States. NSIHT study will improve overall safety, utility, and effectiveness using real-world evidence.

 

2025 Data Report Coming September 2026

Use of Psychedelic Substances in the United States, 2024

Latest Data Report (2024)

The Five Key Findings:

  • Psychedelic substance use was highest among younger adults. 

  • Psilocybin was the most used psychedelic 

  • Use varied by geographic region

  • Psychedelics were perceived to improve mental health
  • Most common settings of use included use with friends or family and in small private settings

 

Click to download Report

 

About NSIHT

NSIHT is the largest ongoing survey of adults using psychedelics in the U.S., providing critical data to improve safety and effectiveness. NSIHT has launched three times since 2024, expecting it’s fourth data collection period in Winter 2025. NISHT is designed to study the context surrounding how adults use these substances, including detailed measurements of behaviors related to the use of specific substances. The survey also monitors changes in psychedelic use over time.

 

 

What We Track  

17 psychedelic substances including both pharmaceutical and recreational forms including classic psychedelic, empathogenic, and dissociative substances
Behaviors surrounding use 
Outcomes of use
Characteristics of the people who use psychedelics 

 

 

Who Uses Our Data  

Researchers • Government Agencies • Clinicians • Policymakers

 

 

Survey Methods  

  • Design: Repeat cross-sectional online survey, conducted twice yearly

  • Participants: U.S. adults (18+) who used psychedelics in the past year

  • Coverage: Nationally representative across all states

  • Quality: Validated methodology with 2+ years of development

  • Funding: 

    • Initial development of pilot funded through US Substance Abuse and Mental Health Administration (SAMHSA) Grant No. 75S20124P00003 with ongoing support under #75S20124P00003 and #75S20321F4200 

    • NSIHT is also supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R01DA064612 

    • The study content is owned and operated by Denver Health and Hospital Authority’s Rocky Mountain Poison & Drug Safety

 

 

Work With Us

Our data supports evidence-based decisions in policy, clinical practice, and research. We can provide technical reports with data insights, limited datasets, or expert consultation. 

Contact: info@rmpds.org

To learn more or for collaboration opportunities & additional survey capabilities, please contact us

 

 

FAQ

  • How often is new data collected? Twice yearly, with annual comprehensive reports.

  • Is participation confidential? Yes, completely anonymous and confidential.

  • How is the data nationally representative? Through strategic oversampling and statistical transport weighting and data fusion techniques.

  • Where can I learn more about the survey methodologies? NSIHT is registered on Open Science Framework.

 

 

Learn More:

NSIHT Current Bibliography

Read the full NSIHT bibliography at this link. Key publications are highlighted below:  

 

  • Rockhill KM, Bemis EA, Schow N, Olsen HA, Beekman K, Fox EJ, Monte AA, Black JC. Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study. J Med Internet Res. 2026 Apr 27;28:e86059. doi: 10.2196/86059.

 

  • Lyons FE, Rockhill KM, Fox EJ, et al. Psychedelic Terminology Preference in the 2024 National Survey Investigating Hallucinogenic Trends (NSIHT). J Psychoactive Drugs. Published online March 16, 2026. doi:10.1080/02791072.2026.2644863

 

  • Chwyl C, Ladka MS, Black JC, Rockhill KM, Dart RC, Luoma JB, Monte AA. Prevalence and predictors of sexual and physical violence during psychedelic use in a US population-based study. World Psychiatry. 2026 Jun;25(2):333-334. doi: 10.1002/wps.70071.  

 

  • Black JC, Rockhill KM, Fox EJ, Jewell JS, Dart RC, Monte AA. Psychedelic Trips: Travel Within the United States to Use Psychedelic Drugs After Legalization. Ann Emerg Med. 2025;86(5):456-462. doi:10.1016/j.annemergmed.2025.05.016      
     

NSIHT Psychedelic Survey Research

National population survey monitoring the real-world use of psychedelics to understand prevalence of use, context of use, benefits, and harms.


Learn More

National Drug Use Surveys

National Drug Use Survey Capabilities

 

RMPDS is a leader in online population health surveys to capture drug use behaviors across the US and Canada.

National drug use surveys are a critical component of RMPDS’s mosaic surveillance methods, providing a robust way to measure prevalence of drug use and associated behaviors. Through rigorous survey design and online panel engagement, our tools capture prescription and over-the-counter medications, illicit drugs, cannabis, and other substances. 

These data are used by federal agencies including the FDA, Health Canada, and SAMHSA, state governments, drug sponsors, and advocacy and public health interest groups. 
 

Learn more about our National Drug Use Survey capabilities:

•    In 2025 Rocky Mountain will survey more than 131,400 people in the United States and Canada and more than 487,000 people since 2019
•    Survey design best practices: reliability testing, validation measures, and careless response mitigation
•    Ability to reach special populations: Veterans, students, racial groups, older adults, adolescents
•    Customize: deploy quickly with stakeholder-specific survey questions
•    Follow up and longitudinal methods: follow-up surveys and longitudinal follow up
 

Survey insights include:

  • Detailed demographics
  • National, Regional, and state level precision, census regions  
  • Validated health measures  
  • Drug specificity, down to formulations   
  • Designed to differentiate between illicit and Rx
  • Participant symptomology
  • Reason for use
  • Recency/frequency of use
  • Perceived benefits
  • Health history
  • Adverse events
 


 

 

NSIHT: National Survey Investigating Hallucinogenic Trends

National population survey monitoring the real-world use of psychedelics to understand prevalence of use, context of use, benefits, and harms.


Learn More

COUNTS: Cannabis Outcomes & Use National Target Survey

Investigation designed to provide comprehensive understanding of cannabis use and trends of use within specific cannabis formulations.


Learn More

GOLDS: General Online Longitudinal Drug Survey

Longitudinal study established to further define best practices in survey design, deployment, bias detection in survey behaviors and how drug use trajectories change as individuals lived experiences change.


Learn More

NMURx: Survey of Non-medical Use of Prescription Drugs

This survey describes medication use without a doctor’s prescription and use outside what a doctor has prescribed. Prescription drugs include: opioids, sedatives, stimulants, and tranquilizers. 


Learn More

OTC: Survey of Over the Counter Medications

A fit-for-purpose survey that provides insight into the behaviors, preferences, safety, and effectiveness of over-the-counter medications and other consumer products among adults and adolescents in the US.


Learn More

Custom Built: Work with our team to design your study

Let’s discuss your research needs, our team is prepared to provide study design surveys, IRB submission, survey deployment and data collection and management services.


Learn More

Learn More About Our Psychedelic Studies

National Survey Investigating Hallucinogenic Trends (NSIHT)

Summary

NSIHT focuses on individuals actively using psychedelics to inform overall safety, utility, and effectiveness using real-world evidence. This cross-sectional surveillance pilot study intends, over time, to be the most comprehensive study of psychedelic use in the United States. It was informed through focus groups and underwent external expert reviews. 

Launched in April of 2024, the survey has over 4,300 respondents to date, capturing the following data: 

Development of pilot funded through US Substance Abuse and Mental Health Administration (SAMHSA) contract #A23-0105-00_9810

 

To learn more or for collaboration opportunities & additional survey capabilities, please contact us

Sentinel Poison Center

Summary

This is a surveillance system of psychedelic drug exposures reported to US Poison Centers. The primary purpose of this study is to quantify and monitor the number of adverse events and medical outcomes associated with psychedelic drug use reported to US poison centers. 

This augmented approach to poison center data collection will capture contextual and clinical variables currently not well captured by poison centers.

The Sentinel poison center program is currently collecting data on psychedelic safety in 4 states (Colorado, Hawaii, Nevada, and Montana).

RMPDS Sentinel Poison Center Program

 

To learn more or for collaboration opportunities, please contact us

Longitudinal Psychedelic Treatment Study - Healing Centers

As new psychedelic drugs emerge, understanding their real-world safety and effectiveness is crucial. Treatments like psilocybin and ketamine are being explored for mental health conditions, with FDA-approved esketamine already available for treatment-resistant depression. While promising, these treatments come with potential risks and benefits that need thorough investigation.

The Healing Centers study is an observational, longitudinal project that will collect patient data over approximately one year. It aims to gather:

  • Demographic and medical history to describe participants.
  • Pre- and post-treatment data to analyze changes in mental health symptoms and overall wellbeing.
  • Quantitative and qualitative experiences to identify any negative outcomes or adverse events.

Key measures will include patient perceptions of health, wellbeing, social support, psychological insight, and serious adverse events like hospitalization.

Data collection is active in 15 clinics in 7 states.

Current Site Enrollment Locations:

Healing Centers current site enrollment map

For more information about our Longitudinal Psychedelic Treatment Study - Healing Centers program or to enroll, please contact us


Psychedelic Studies

Fit-for-Purpose Data Collection


 

Rocky Mountain leads the development of fit-for-purpose surveillance tools to monitor the safety and effectiveness of psychedelic therapies. Well-designed tools are important to maximizing the safe use of these therapies. The application of these psychedelic safety and effectiveness data include public health monitoring, premarket safety evaluations, and REMS evaluations.

 

We work alongside many brands to provide data & insights that matter.

Monitoring for Brands that Matter

 

 

National Survey Investigating Hallucinogenic Trends (NSIHT)

National population survey monitoring the real-world use of psychedelics to understand prevalence of use, context of use, benefits, and harms.


Learn More

Sentinel Poison Center

Surveillance of psychedelic safety at US poison centers through augmented data collection methods.


Learn More

Longitudinal Psychedelic Treatment Study

An observational, longitudinal study to understand the outcomes, impact, and participant journeys of psychedelic and dissociative treatments for mental health.


Learn More

Publications

Our team is disseminating the results of our work through manuscripts, abstracts, and presentations.


Learn More

Rocky Mountain Data Collection Leadership

We are led by a multi-disciplinary team of clinical, scientific, and methodological experts.


Learn More

Ready To Explore?

We are eager to discuss with you how we can help you meet your psychedelic data collection needs.


Learn More

Public Access Data

Access Data Here


Contact Us

Rocky Mountain leads the development of fit-for-purpose surveillance tools to monitor the safety and effectiveness of psychedelic therapies. Well-designed tools are important to maximizing the safe use of these therapies. The application of these psychedelic safety and effectiveness data include public health monitoring, premarket safety evaluations, and REMS evaluations

Public Data

Drug Use in the United States


This dashboard highlights data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System which has been monitoring drug use since 2006. We pride ourselves on combining data across sources to provide a more accurate and complete picture of drug use in the United States. 

Explore our dashboard below! Each tab focuses on a different facet of drug use, misuse, abuse, and diversion. On any page, use the tabs at the top to navigate to a topic of interest and the selection tool on the right to choose the type of drug you are interested in learning more about. Hover over data to see more detail.


 

Learn More About Our Postmarketing Surveillance

Mosaic Surveillance & Triangulation

  • Web population survey
  • Therapeutic use of psychedelics
  • Non-therapeutic substance use
  • Acute health effects
  • Mortality data
  • Drug transaction data
  • Street price information
  • Web discussion

 

For more information about mosaic surveillance and triangulation, please contact us

Observational Studies

  • Study design
  • Real-world data
  • Data collection and management
  • Epidemiological studies
  • Longitudinal studies
  • Biostatistical analysis
  • Custom-built research tools

For more information about observational studies, please contact us

National Poison Data System Studies

  • Outcomes with intentional and unintentional exposures
  • Adverse event information
  • Data on special populations -- suicide, children, older adults

 

For more information about National Poison Data System studies, please contact us

Literature Surveillance

  • Customized search strategies
  • Continuous monitoring
  • Synthesis of insights

 

For more information about literature surveillance, please contact us

Benchmarking and Safety

  • Signal detection
  • Human abuse potential study design
  • Retrospective and prospective data
  • Diversion risk
  • History, trends, and patterns of use

 

For more information about benchmarking and safety, please contact us


Patient Health & Medical Toxicology Services Learn More

Telemedicine

Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32. The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.

Clinical Care

Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32. The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.

Medical Toxicology Training

Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32. The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.

Healthcare System Navigation

Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32. The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.

Publications/Posters

Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32. The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.

Patient Stories

Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32. The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.


Consulting

Adverse Event Signal Detection

  • Data analysis and interpretation
  • Risk assessment
  • Medical information and pharmacovigilance
  • Acute health effects

 

For more information about adverse event signal detection, please contact us

Data Analytics

  • Data integration and visualization
  • Advanced analytics
  • Real-time monitoring

 

For more information about data analytics, please contact us

Study Design & Protocol Development

  • Methodology development
  • Risk assessment
  • Reporting and dissemination
  • Regulatory compliance

 

For more information about study design and protocol development, please contact us

Public Health Responses

  • Safety signal management
  • Public health communication
  • Risk management plans
  • Education and training
  • US State data on drug use

 

For more information about public health responses, please contact us

Toxicology

  • Board-certified medical toxicologists
  • Adverse event management
  • Product development
  • Education and training

 

For more information about toxicology, please contact us

Database Development

  • Adverse event reporting
  • Signal detection and assessment
  • Product quality complaints

 

For more information about database administration and development, please contact us


Medical Information & Pharmacovigilance Learn More

Streamlined Adverse Event & Product Complaint Intake

  • Predominate expert PharmD Staff
  • HCP agent live answer (we never use non-HCP to triage calls)
  • Robust initial data collection and documentation
  • Premium reporting and data utiliztaion
  • Expert recognition of hidden events with mature probing for more complete reports

For more information about streamlined adverse event and product complaint intake, please contact us

International Telephony

  • Multi-channel configuration
  • Robust IVR configurability
  • Reportable non-recorded lines for privacy regulation compliance
  • Disaster recovery/redundant systems
  • Call recording for quality review
  • Speech analytics and AI quality monitoring

For more information about international telephony, please contact us

Pharmacovigilance

  • On-time regulatory submissions and reporting
  • Aggregate, periodic and expedited reporting (PSUR and PADAR, etc.)
  • Data migration
  • SDEA
  • Agency audit support
  • Literature surveillance
  • Risk management services
  • MedDRA and WHO drug coding

For more information about pharmacovigilance, please contact us

Turnkey Medical Information Database

  • Internal clinical system implementation administrators
  • Streamlined onboarding and client-specific modifications
  • Customized data collection configurations 
  • Fully validated system incorporating regulatory and privacy requirements

For more information about turnkey medical information database, please contact us

Medical Information Insights

  • Industry standards through best practices
  • Real-time, interactive, configurable dashboards
  • Customized data points
  • PharmD analysis 

For more information about medical information insights, please contact us

System integrations

  • Bi-directional CRM integrations
  • Content integrations with industry standard document repositories
  • PV and quality system integration (XML output)
  • CRM Contact integrations
  • Portal webform intake

For more information about system integrations, please contact us


Scientific Communication Learn More

Publication Strategies

  • Literature reviews and meta-analyses
  • Manuscript writing
  • Conference abstract and presentation generation
  • Collaborative research and authorship
  • Regulatory submissions and white papers

 

For more information about publication strategies, please contact us

Medical Writing

  • Clinical trial documentation
  • Adverse event reports
  • Educational and training materials
  • Medical and safety communications

 

For more information about medical writing, please contact us


Subscribe to